Journals / Turkish Journal of Gastroenterology / 2004 / Cilt: 15 - Sayı: 4

Rabeprazol’un tek başına veya H$H_2$ reseptor ile kombine kullanımının intrahepatik pH üzerine etkisi: Pilot çalışma

The effect of rabeprazole alone or in combination with $H_2$ receptor blocker on intragastric pH: A pilot study

Pages
225–228
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Use of H2 receptor blockers and proton pump inhibitors in combination to control intra-gastric pH is more beneficial.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aims: Proton pump inhibitors have been widely used in recent years.
📊
Key Findings & Data:It has therefore been suggested that H2 receptor blockers should be added to the therapy.
💡
Conclusion & Impact:Use of H2 receptor blockers and proton pump inhibitors in combination to control intra-gastric pH is more beneficial.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Histamin H2 antagonistleri · Dispepsi · Mide asidi

Abstract

Background/aims: Proton pump inhibitors have been widely used in recent years. However, there are studies suggesting that proton pump inhibitors may not control the gastric acidity effectively during the night, especially in gastroesophageal reflux disease. It has therefore been suggested that H2 receptor blockers should be added to the therapy. The aim of our study was to evaluate the effects of proton pump inhibitors alone or in combination with H2 receptor blockers on gastric acidity with 24-hour gastric pH monitoring. Methods: Esophagogastroscopy and 24-hour gastric pH monitoring were performed on 10 patients with dyspeptic symptoms. No patient had anacidity. All patients had erosive antral gastritis. Patients were randomized to two groups as either proton pump inhibitor therapy group (rabeprazole 20 mg/day, p.o.) or proton pump inhibitor + H2 receptor blocker therapy group (rabeprazole 20 mg/day, p.o. + famotidine 40 mg/day, p.o). After one month of treatment, 24-hour gastric pH monitoring was re-performed. Results: Seven female and three male patients were enrolled into the study. The mean age was 51.1±11.56 years. All patients had antral erosive gastritis. Gastric pH was measured as less than 4 in 81.4% of the 24-hour period prior to rabeprazole treatment. With rabeprazole treatment this ratio decreased to 27.6% (p<0.05). These ratios were 86.3% and 4.55%, respectively, in the group that received combination therapy (p<0.05). Conclusions: Combination therapy with H2 receptor blockers and proton pump inhibitors seemed to control intra-gastric pH better than proton pump inhibitors alone. Use of H2 receptor blockers and proton pump inhibitors in combination to control intra-gastric pH is more beneficial.

Özet

Amaç: Proton pompa inhibitörlerinin kullanımı son yıllarda giderek artmaktadır. Ancak özellikle gastroözofajiyal hastalarında proton pompa inhibitörü kullanımının gece tam olarak gastrik asiditeyi kontrol etmediği ve bu yüzden tedaviye H2 reseptör blokerlerinin eklenmesi gerektiği savunulmaktadır. 24 Saatlik gastrik pH monitorizasyonu ile proton pompa inhibitörü kullanımı ve proton pompa inhibitörü + H2 reseptör blokeri kullanımının gastrik asidite üzerine etkilerini karşılaştırmaktır. Yöntem: Çalışmaya dispeptik semptomlarla başvuran 10 hasta dahil edildi. Bu hastaların hepsine üst gastrointestinal sistem endoskopisi yapılldıktan sonra, 24 saatlik gastrik pH monitorizasyonu uygulandı. Hastaların hiç birisinde anasidite mevcut değildi. Hastalar 2 gruba ayrıldıktan sonra bir gruba sadece proton pompa inhibitörü (Rabeprozol 20 mg/gün, po), diğer gruba ise proton pompa inhibitörü + H2 reseptör blokeri (Rabeprozol 20 mg/gün p.o.+ Famotidin 40 mg/gün p.o.) 1 ay süre ile tatbik edildi. 1 ay sonunda 24 saatlik gastrik pH monitorizasyonu tekrarlandı. Bulgular: Çalışmaya 7 bayan, 3 erkek hasta alındı. Hastaların ortalama yaşı 51.1±11.56 yıl idi. Çalışmaya alınan hastaların hepsinde eroziv antral gastrit mevcut idi. Proton pompa inhibitörü verilen grupta tedavi öncesi gastik pH’nın <4 olduğu zaman %81.4 iken tedavi sonrası bu oran %86.3 iken tedavi sonrası bu oran %4.55’e düştü (p<0.05). Sonuç: Proton pompa inhibitörleri ile H2 reseptör blokerlerinin kombinasyonu gastrik asidiyeti tek başına proton pompa inhibitörü tedavisine oranla daha belirgin olarak kontrol etmektedir. İntragastrik asidite supresyonunda proton pompa inhibitörü H2 reseptör blokerlerinin kombine kullanılması daha faydalı olacaktır.

🔖

Cite This Article

TÖRÜNER, M., BEKTAŞ, M., ÇETİNKAYA, H., SOYKAN, İ., ÖZDEN, A. (2004). Rabeprazol’un tek başına veya H$H_2$ reseptor ile kombine kullanımının intrahepatik pH üzerine etkisi: Pilot çalışma. Turkish Journal of Gastroenterology, Cilt: 15 - Sayı: 4, 225–228. https://ajindex.com/articles/410432

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Maton PN. Omeprazole. N Engl J Med 1991
  2. 324(14): 965-75. 2.Hunt RH. pH and Hp-gastric acid secretion and Helicobacter pylori: implications for ulcer healing and eradication of the organism. Am J Gastroenterol 1993
  3. 88(4): 481-3. 3.Muller P, Dammann HG, Leucht U, et al. Human gastric acid secretion following repeated doses of AG-1749. Aliment Pharmacol Ther 1989
  4. 3(2): 193-8. 4.Simon B, Muller P, Marinis E, et al. Effect of repeated oral administration of BY 1023/SK&F 96022-a new substituted benzimidazole derivative—on pentagastrin-stimulated gastric acid secretion and pharmaeokinetics in man. Ali ment Pharmacol Ther 1990
  5. 4(4): 373-9. 5.Yasuda S, Ohnishi A, Ogawa T, et al. Pharmacokmetic properties of E3810, a new proton pump inhibitor, in healthy male volunteers. Int J Clin Pharmacol Ther 1994
  6. 32(9): 466-73. 6.Galmiche JP, Bruley Des Varannes S, Ducrotte P, et al. Tenatoprazole, a. novel proton pump inhibitor with a prolonged plasma half-life:.effects on intragastric pH and comparison with esomeprazole in healthy volunteers. Aliment Pharmacol Ther 2004
  7. 19(6): 655-62. 7.Lind T, Rydberg L, Kyleback A, et al. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000
  8. 14(7): 861-7. 8.Peghini PL, Katz PO, Bracy NA, et al. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 1998
  9. 93(5): 763-7. 9.Peghini PL., Katz PO, Castell DO. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 1998
  10. 115(6): 1335-9. 10.Xue S, Katz PO, Benerjee P, et al. Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors. Aliment Pharmacol Ther 2001
  11. 15(9): 1351-6. 11.Katsube T, Adachi K, Kawamura A, et al. Helicobacter pylori infection influences nocturnal gastric acid breakthrough. Aliment Pharmacol Ther 2000
  12. 14(8): 1049-56. 12.Ohning GV, Barbuti RC, Kovacs TO, et al. Rabeprazole produces rapid, potent, and long-acting inhibition of gastric acid secretion in subjects with Helicobacter pylori infection. Aliment Pharmacol Ther 2000
  13. 14(6): 701-8. 13.Robinson M. New-generation proton pump inhibitors: over coming the limitations of early-generation agents. Eur J Gastroenterol Hepatol 2001
  14. 13 Suppl 1: S43-7. 14.Katz PO, Frissora C. The pharmacology and clinical rele vance of proton pump inhibitors. Curr Gastroent